What is Benchling?
Founded over a decade ago by scientists who recognized the need for better technology in academic research, Benchling has evolved into a leading platform for biotechnology companies. The company provides a comprehensive suite of tools designed to support the complex workflows and collaborative needs of modern life sciences. By digitizing and streamlining research and development processes, Benchling empowers organizations, from startups to global enterprises, to accelerate the discovery and development of new medicines, crops, foods, and materials. Its platform is instrumental in driving the ongoing biotech revolution.
How much funding has Benchling raised?
Benchling has raised a total of $418.9M across 9 funding rounds:
Angel/Seed
$900K
Unspecified
$5M
Private Equity
$7M
Series A
$7M
Series B
$14.5M
Series C
$34.5M
Series D
$50M
Series E
$200M
Series F
$100M
Angel/Seed (2014): $900K with participation from Y Combinator and Rock Health companies
Unspecified (2015): $5M led by Andreessen Horowitz and Thrive Capital
Private Equity (2016): $7M supported by Thrive Capital and Andreessen Horowitz
Series A (2016): $7M featuring Matt Huang, Ashton Kutcher Network, Geoff Ralston, Thrive Capital, and Andreessen Horowitz
Series B (2018): $14.5M backed by F-Prime Capital Partners, Benchmark Capital, and Thrive Capital
Series C (2019): $34.5M with participation from Lead Edge Capital Management, Benchmark, Menlo Ventures, Y Combinator Continuity, and Thrive Capital
Series D (2020): $50M led by Spark Capital, ICONIQ Partners, Benchmark, Thrive Capital, Alkeon Capital Management LLC, and Lux Capital
Series E (2021): $200M supported by Elad Gil, Thrive Capital, Lux Capital, Benchmark Holdings, Sequoia Capital Global Equities, ICONIQ Capital, Lead Edge Capital Management, Altimeter Capital, Byerly Capital, Alkeon Capital Management, Menlo Ventures, and Spark Capital
Series F (2021): $100M, investors not publicly disclosed
Key Investors in Benchling
Thrive Capital
Thrive Capital is an investment venture capital company that operates out of New York, primarily dealing in internet and software investments.
Benchmark
Benchmark is a venture capital firm known for investing in early-stage technology companies.
Lux Capital
Lux Capital is a New York-based venture capital firm investing in early-stage and growth-stage companies at the intersection of science and technology.
What's next for Benchling?
The recent major strategic investment indicates Benchling's strong position and future potential within the rapidly expanding biotechnology landscape. This capital infusion is expected to fuel further product development, enhance its platform capabilities, and expand its global reach. As the company continues to scale, it is poised to play an even more significant role in enabling scientific breakthroughs and shaping the future of biotechnology. Benchling's strategic financing suggests a focus on solidifying its market leadership and driving innovation in life sciences.
See full Benchling company page
